HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US House Committee Requests Proof Of FDA Progress Seizing Opioids In International Mail

This article was originally published in The Pink Sheet

Executive Summary

Energy & Commerce's Republican and Democrat leadership ask FDA Commissioner Scott Gottlieb about work by the agency's Office of Criminal Investigations focused on opioid drugs, the office's staffing and its priorities. They note FDA's FY2018 appropriation included $94m for its work in international mail facilities.

You may also be interested in...



FDA Using Ion Mobility Spectrometers In 4 IMFs, Plans Use In 4 More

Across all 9 IMF facilities in FY 2019, FDA screened around 25,200 parcels containing more than 41,000 products, detained more than 38,000 including 1,801 identified as supplements and expects to destroy more than 17,000.

FDA Consumer Health Market Oversight Stays In Spotlight In Gottlieb's Final Week

In four days before Scott Gottlieb's stint as commissioner ended, FDA announced official start of initiative to consider regulatory pathways to make CBD compliant as a dietary ingredient, launched another shot across kratom sector's bow and noted more examples of e-cigarette marketers crossing regulatory lines.

US International Mail Shipment Searches Reap More Spiked Supplements

Between start of federal government partial shutdown on Dec. 22 and federal agencies' re-opening on Jan. 28, FDA Customs and Border Protection officials examining international mail shipments found ED drugs in six products and two weight loss ingredients approved in the US in four.

Related Content

Topics

UsernamePublicRestriction

Register

RS122612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel